Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Legal Officer

Chief Development Officer

Chief Financial Officer

President and CEO

Chief Medical Officer

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase Ã‚Â½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-06	Premium	sold	Premium	Premium	Premium	-
2024-05-02	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-05-02	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-04-29	Premium	sold	Premium	Premium	Premium	-
2024-04-29	Premium	sold	Premium	Premium	Premium	-
2024-04-22	Premium	sold	Premium	Premium	Premium	-
2024-04-15	Premium	sold	Premium	Premium	Premium	-
2024-04-15	Premium	acquired	Premium	Premium	Premium	-
2024-04-15	Premium	sold	Premium	Premium	Premium	-
2024-04-08	Premium	sold	Premium	Premium	Premium	-
2024-04-04	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-04-04	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	-
2024-03-28	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-03-28	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-03-27	Premium	sold	Premium	Premium	Premium	-
2024-03-25	Premium	sold	Premium	Premium	Premium	-
2024-03-25	Premium	sold	Premium	Premium	Premium	-
2024-03-22	Premium	sold	Premium	Premium	Premium	Chief Development Officer
2024-03-22	Premium	acquired	Premium	Premium	Premium	Chief Development Officer
2024-03-15	Premium	acquired	Premium	Premium	Premium	-
2024-03-15	Premium	sold	Premium	Premium	Premium	-
2024-01-05	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-01-05	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-05	Premium	acquired	Premium	Premium	Premium	Chief Development Officer

NUVL - Nuvalent, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for NUVL